Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지

Linezolid Treatment for Osteomyelitis due to Staphylococcus Epidermidis with Reduced Vancomycin Susceptibility

  • Nam, Joon-Rok (Department of Neurosurgery, Seoul Paik Hospital Inje University College of Medicine) ;
  • Kim, Myoung-Soo (Department of Neurosurgery, Seoul Paik Hospital Inje University College of Medicine) ;
  • Lee, Chae-Heuck (Department of Neurosurgery , Seoul Paik Hospital Inje University College of Medicine) ;
  • Whang, Dong-Hee (Department of Laboratory Medicine, Seoul Paik Hospital Inje University College of Medicine)
  • Published : 2008.06.13
Download PDF
⟨ Previous Next ⟩

Abstract

Limited therapeutic options are available for vancomycin intermediate-resistant Staphylococcus epidermidis (VISE) infections and no optimum therapy has been established. We report a case of VISE skull osteomyelitis that was successfully treated with linezolid. The patient was a 53-year-old man who presented with headache, nausea and dysphasia. Brain computerized tomography (CT) demonstrated a subdural hematoma in the left hemisphere. Craniotomy and hematoma evacuation was performed and he showed good recovery despite a scalp wound infection caused by methicillin-resistant Staphylococcus aureus (MRSA). The organism isolated from the scalp wound was sensitive to vancomycin. The patient was treated with intravenous vancomycin for 44 days. However, he showed a high fever, persistent positive methicillin-resistant Staphylococcus epidermidis (MRSE) blood cultures, and a deteriorating clinical status. He underwent infected skull bone flap removal and linezolid treatment for 35 days. During one year of follow up, he has not had any further episodes of osteomyelitis or fever. Linezolid has shown to be effective agent to eradiate osteomyelitis caused by VISE.

Keywords

References

  1. Bodogan B, Appelbaum PC : Oxazolidinones : activitiy, mode of action, and mechanism of resistance. Int J Antimicrob Agents 23 : 113-119, 2004 https://doi.org/10.1016/j.ijantimicag.2003.11.003
  2. Davenport DS, Massanari RM, Pfaller MA, Bale MJ, Streed SA, Hierholzer WJ Jr : Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. J Infect Dis 153 : 332-339, 1986 https://doi.org/10.1093/infdis/153.2.332
  3. Dunne WM Jr, Qureshi H, Pervez H, Nafziger DA : Staphylococcus epidermidis with intermediate resistance to vancomycin : elusive phenotype or laboratory artifact? Clin Infect Dis 33 : 135-137, 2001 https://doi.org/10.1086/320890
  4. Farber BF, Kaplan MH, Cloqston AG : Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis 161 : 37-40, 1990 https://doi.org/10.1093/infdis/161.1.37
  5. Garrett DO, Jochimsen E, Murfitt K, Hill B, McAllister S, Nelson P, et al : The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 20 : 167-170, 1999 https://doi.org/10.1086/501605
  6. Kaatz GW, Seo SM : In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 40 : 799-801, 1996
  7. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM : Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 50 : 747-750, 2002 https://doi.org/10.1093/jac/dkf207
  8. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ : Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 32 : 8-14, 2004 https://doi.org/10.1007/s15010-004-3029-9
  9. Schwalbe RS, Ritz WJ, Verma PR, Barranco EA, Gilligan PH : Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis 161 : 45-51, 1990 https://doi.org/10.1093/infdis/161.1.45
  10. Schwalbe RS, Stapleton JT, Gilliqan PH : Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316 : 927-931, 1987 https://doi.org/10.1056/NEJM198704093161507
  11. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, et al : Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 36 : 1020-1027, 1988
  12. Veach LA, Pfaller MA, Barrett M, Koontz FP, Wenzel RP : Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 28 : 2064-2068, 1990
  13. Wong SS, Ho PL, Woo PC, Yuen KY : Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 29 : 760-767, 1999 https://doi.org/10.1086/520429
  14. Woodford N, Johnson AP, George RC : Detection of glycopeptide resistance in clinical isolates of gram-positive bacteria. J Antimicrob Chemother 28 : 483-486, 1991 https://doi.org/10.1093/jac/28.4.483